Cargando…

Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg‐Negative CHB

Treatment with nucleos(t)ide analogues (NAs) may be stopped after 1‐3 years of hepatitis B virus DNA suppression in hepatitis B e antigen (HBeAg)‐negative patients according to Asian Pacific Association for the Study of Liver and European Association for the Study of Liver guidelines. However, virol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wübbolding, Maximilian, Lopez Alfonso, Juan Carlos, Lin, Chun‐Yen, Binder, Sebastian, Falk, Christine, Debarry, Jennifer, Gineste, Paul, Kraft, Anke R.M., Chien, Rong‐Nan, Maasoumy, Benjamin, Wedemeyer, Heiner, Jeng, Wen‐Juei, Meyer Hermann, Michael, Cornberg, Markus, Höner zu Siederdissen, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789842/ https://www.ncbi.nlm.nih.gov/pubmed/33437904 http://dx.doi.org/10.1002/hep4.1626

Ejemplares similares

Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
por: Kim, Young Jip, et al.
Publicado: (2013)

Study on Post-Treatment Relapse in HBeAg Positive CHB Patients
por: Lu, Junfeng, et al.
Publicado: (2015)

HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis
por: Xing, Tongjing, et al.
Publicado: (2017)

Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative
por: He, Dengming, et al.
Publicado: (2013)

Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues
por: Broquetas, Teresa, et al.
Publicado: (2017)

Baseline serum miR-125b levels predict virologic response to nucleos(t)ide analogue treatment in patients with HBeAg-positive chronic hepatitis B
por: Zhou, Pu, et al.
Publicado: (2018)

Caucasian Ethnicity, but Not Treatment Cessation Is Associated with HBsAg Loss Following Nucleos(t)ide Analogue-Induced HBeAg Seroconversion
por: Van Hees, Stijn, et al.
Publicado: (2019)

Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues
por: Wang, Yang, et al.
Publicado: (2022)

MAFLD is Associated with the Risk of Liver Fibrosis and Inflammatory Activity in HBeAg-Negative CHB Patients
por: Chen, Xiaoman, et al.
Publicado: (2022)

Potential Efficacy of Pegylated Interferon-α and a Nucleos(t)ide Analogue as Combination Therapy for HBeAg-Positive Chronic Hepatitis B
por: Wi, Chung-Il, et al.
Publicado: (2016)

Editorial: serum HBV RNA biphasic decline in patients with HBeAg‐positive chronic hepatitis B treated with nucleos(t)ide analogues
por: Ding, Yang, et al.
Publicado: (2020)

Serum IL-21 levels predict HBeAg decline during rescue therapy in patients with partial response to nucleos(t)ide analogues
por: Li, Yue, et al.
Publicado: (2021)

Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis B
por: van Bömmel, Florian, et al.
Publicado: (2021)

Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients
por: Scheller, Laura, et al.
Publicado: (2021)

PP-084 Early virologic response predicts therapeutic outcomes in adefovir-treated HBeAg-positive chronic hepatitis B (CHB) patients
por: Hou, J.L., et al.
Publicado: (2008)

Serum Hepatitis B Virus RNA Levels Predict HBeAg Seroconversion and Virological Response in Chronic Hepatitis B Patients with High Viral Load Treated with Nucleos(t)ide Analog
por: Ji, Xin, et al.
Publicado: (2020)

HBeAg-positive patients with HBsAg < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation
por: Xie, Yandi, et al.
Publicado: (2021)

Circulating miR-122 Is a Predictor for Virological Response in CHB Patients With High Viral Load Treated With Nucleos(t)ide Analogs
por: Wu, Yin, et al.
Publicado: (2019)

Favorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG
por: Ho, Cheng-Hsun, et al.
Publicado: (2017)

HBsAg Dampened STING Associated Activation of NK Cells in HBeAg-Negative CHB Patients
por: Zheng, Bingqing, et al.
Publicado: (2021)

Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes
por: Van Hees, S., et al.
Publicado: (2018)

Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019
por: Maisa, Anna, et al.
Publicado: (2021)

Effect of Telbivudine Versus Other Nucleos(t)ide Analogs on HBeAg Seroconversion and Other Outcomes in Patients with Chronic Hepatitis B: A Network Meta-Analysis
por: Liang, Xieer, et al.
Publicado: (2016)

Predictors of HBeAg seroconversion after long-term nucleos(t)ide analogues treatment for chronic hepatitis B: a multicenter study in real clinical setting
por: Yu, Weiyan, et al.
Publicado: (2017)

Using machine learning models to predict HBeAg seroconversion in CHB patients receiving pegylated interferon‐α monotherapy
por: Shang, Hongyan, et al.
Publicado: (2022)

Corrigendum: Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019
por: Maisa, Anna, et al.
Publicado: (2022)

Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study
por: Chen, Yi-Cheng, et al.
Publicado: (2020)

Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis
por: Zhao, Pan, et al.
Publicado: (2011)

Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs
por: Cai, Shaohang, et al.
Publicado: (2018)

Anti-HBc IgG Levels: A Predictor of HBsAg Seroclearance in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue-Induced HBeAg Seroclearance
por: Kim, Saein, et al.
Publicado: (2021)

Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort study
por: Sonneveld, Milan J., et al.
Publicado: (2023)

Analysis of clinical and virologic features in Hepatitis B e Antigen (HbeAg)-negative and HbeAg-positive Egyptian chronic hepatitis B patients
por: Fouad, Rabab, et al.
Publicado: (2020)

Differential Plasma MicroRNA Profiles in HBeAg Positive and HBeAg Negative Children with Chronic Hepatitis B
por: Winther, Thilde Nordmann, et al.
Publicado: (2013)

Profiling of Peripheral TRBV and CD4+CD25+ Treg in CHB Patients with HBeAg SC during TDF Treatment
por: Yang, Jiezuan, et al.
Publicado: (2023)

Effect of switching from nucleos(t)ide maintenance therapy to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomized trial
por: Woo, Hyun Young, et al.
Publicado: (2022)

Immune drivers of HBsAg loss in HBeAg-negative CHB patients after stopping nucleotide analog and administration of Peg-IFN
por: Islam, Mojahidul, et al.
Publicado: (2023)

Correlations of HBV Genotypes, Mutations Affecting HBeAg Expression and HBeAg/ anti-HBe Status in HBV Carriers
por: Lim, Chee Kent, et al.
Publicado: (2006)

Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues
por: Fan, Rong, et al.
Publicado: (2016)

Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naïve HBeAg-positive patients with chronic hepatitis B: A large, multicentre, randomized controlled trials
por: Cai, Dachuan, et al.
Publicado: (2019)

Frequency of Potential Drug–Drug Interactions in the Changing Field of HCV Therapy
por: Schulte, Benjamin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_aach266etvaf64n85cu3o7nrn9